Abstract
Calcitonin (CT), a peptide hormone that is widely used for the treatment of osteoporosis, Pagets disease, hypercalcemic shock and chronic pain in terminal cancer patients, is produced by the para-follicular cells of the thyroid gland in mammals and by the ultimobranchial gland of birds and fish. Fish calcitonin, like eel calcitonin (eCT), is more potent and longer lasting than human CT and is one of the many bioactive peptides that require C-terminal amidation for full biological activity. In this study we describe the over-expression and over-production of C-terminal amidated eCT in recombinant Streptomyces avermitilis. A phylogenetic analysis was performed with all the known CT amino acid sequences.
Keywords: recombinant eel calcitonin (ect), amidating enzyme, therapeutic protein, pchic9
Protein & Peptide Letters
Title: Overexpression and Purification of Recombinant Eel Calcitonin and Its Phylogenetic Analysis
Volume: 12 Issue: 3
Author(s): Chiranjib Chakraborty, Shyam Sundar Nandi, Biplab Sarkar and S. Sinha
Affiliation:
Keywords: recombinant eel calcitonin (ect), amidating enzyme, therapeutic protein, pchic9
Abstract: Calcitonin (CT), a peptide hormone that is widely used for the treatment of osteoporosis, Pagets disease, hypercalcemic shock and chronic pain in terminal cancer patients, is produced by the para-follicular cells of the thyroid gland in mammals and by the ultimobranchial gland of birds and fish. Fish calcitonin, like eel calcitonin (eCT), is more potent and longer lasting than human CT and is one of the many bioactive peptides that require C-terminal amidation for full biological activity. In this study we describe the over-expression and over-production of C-terminal amidated eCT in recombinant Streptomyces avermitilis. A phylogenetic analysis was performed with all the known CT amino acid sequences.
Export Options
About this article
Cite this article as:
Chakraborty Chiranjib, Nandi Sundar Shyam, Sarkar Biplab and Sinha S., Overexpression and Purification of Recombinant Eel Calcitonin and Its Phylogenetic Analysis, Protein & Peptide Letters 2005; 12 (3) . https://dx.doi.org/10.2174/0929866053587147
DOI https://dx.doi.org/10.2174/0929866053587147 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry The Art of Data Mining the Minefields of Toxicity Databases to Link Chemistry to Biology
Current Computer-Aided Drug Design The Use of Growth Factors in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Current Medicinal Chemistry Effect of Selenium Enrichment of <i>Lenzites betulinus</i> and <i>Trametes hirsuta</i> Mycelia on Antioxidant, Antifungal and Cytostatics Potential
Current Pharmaceutical Biotechnology The Long Term Biological Consequences of Anorexia Nervosa
Current Nutrition & Food Science Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors
Current Cancer Drug Targets Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Current Drug Safety Simultaneous Amplification of HER-2 (ERBB2) and Topoisomerase IIα (TOP2A) Genes - Molecular Basis for Combination Chemotherapy in Cancer
Current Cancer Drug Targets GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry QSPR Model for Dispersibility of Graphene in Various Solvents
Letters in Drug Design & Discovery Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Hydroxamic Acids, Recent Breakthroughs in Stereoselective Synthesis and Biological Evaluations
Current Organic Synthesis Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: 177Lu-PSMA is Set to Redefine Prostate Cancer Treatment)
Current Radiopharmaceuticals Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry